Residency · Residency · Urology
Urinary Tract Infections: Uncomplicated and Complicated
Introduction
Urinary tract infections (UTIs) are among the most common bacterial infections encountered in clinical practice, leading to approximately 8.1 million physician visits annually in the United States. For urologists, it is crucial to understand the full spectrum of UTIs, ranging from uncomplicated cystitis to potentially life-threatening urosepsis. Mastery of accurate classification, appropriate diagnostic evaluation, and evidence-based antimicrobial stewardship forms the foundation of competent urologic care.
Classification of UTIs
Uncomplicated UTIs typically occur in otherwise healthy, non-pregnant, premenopausal women who have no structural or functional abnormalities of the urinary tract. Within this category, uncomplicated cystitis refers to infection confined to the lower urinary tract, while uncomplicated pyelonephritis involves the upper urinary tract in the same low-risk population. Common risk factors for uncomplicated UTIs include sexual intercourse, spermicide use, a prior history of UTIs, and a family history of UTIs.
In contrast, complicated UTIs arise in the context of structural abnormalities, functional impairments, or host compromise. This group includes patients with urinary obstruction, indwelling catheters, neurogenic bladder, renal transplantation, pregnancy, or immunosuppression. Male sex is generally classified as complicated due to anatomical considerations. Complicated UTIs carry a higher risk of treatment failure, infection with resistant organisms, and progression to systemic sepsis.
Recurrent UTIs are defined as two or more infections within six months or three or more infections within twelve months. These recurrences may represent either relapse, where the same organism causes infection within two weeks, or reinfection, involving a new organism or the same organism after two weeks. Evidence-based interventions for recurrent UTIs include behavioral modifications, vaginal estrogen therapy, and antimicrobial prophylaxis.
Microbiology
Escherichia coli is the predominant pathogen, responsible for 75-95% of uncomplicated UTIs and 40-60% of complicated infections. Other common organisms in complicated UTIs include Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. Pseudomonas aeruginosa and Candida species are frequently associated with catheter-related infections. The emergence of extended-spectrum beta-lactamase (ESBL) producing organisms is an increasing concern, especially in recurrent and healthcare-associated UTIs. Uropathogenic E. coli (UPEC) possess virulence factors such as type 1 fimbriae, P fimbriae, alpha-hemolysin, and siderophores that facilitate adhesion, invasion, and iron acquisition.
<image>Diagram illustrating the pathogenesis of ascending urinary tract infection, showing bacterial adhesion to urothelium via fimbriae, ascension from bladder to kidney, and host immune response with neutrophil recruitment</image>
Diagnosis
Clinically, cystitis presents with dysuria, urinary frequency, urgency, suprapubic discomfort, and sometimes hematuria. Pyelonephritis manifests with flank pain, costovertebral angle tenderness, fever, rigors, and nausea or vomiting. Urosepsis involves a systemic inflammatory response originating from a urinary source and may progress to septic shock with hemodynamic instability.
Laboratory evaluation begins with urinalysis and microscopy, which typically reveal pyuria (more than 10 white blood cells per high power field), bacteriuria, nitrites, and leukocyte esterase. Urine culture with antibiotic sensitivities remains the gold standard for diagnosis; significant bacteriuria is defined as at least 10^5 colony-forming units per milliliter (CFU/mL) in clean-catch specimens and at least 10^2 CFU/mL in catheterized specimens. Blood cultures should be obtained in cases of febrile UTI, pyelonephritis, and suspected urosepsis. Procalcitonin levels may assist in distinguishing upper from lower urinary tract infections.
Imaging is not routinely indicated for uncomplicated cystitis. However, renal ultrasound or computed tomography (CT) of the abdomen and pelvis is warranted in complicated UTIs to evaluate for obstruction, abscess formation, or anatomic abnormalities. CT urogram is the preferred imaging modality when renal or perinephric abscess is suspected.
<image>CT scan with contrast showing left perinephric abscess in a patient with complicated pyelonephritis, with annotations highlighting the abscess cavity, surrounding inflammatory stranding, and kidney parenchyma</image>
Treatment
For uncomplicated cystitis, first-line therapy includes nitrofurantoin 100 mg twice daily for five days. Trimethoprim-sulfamethoxazole double strength twice daily for three days is an alternative if local resistance rates are below 20%. Fosfomycin, given as a single 3 g dose, has lower efficacy but is useful against resistant organisms. Fluoroquinolones should be reserved due to concerns about collateral damage and increasing resistance.
| Condition | First-Line Agent | Dose/Duration | Alternatives |
|---|---|---|---|
| Uncomplicated cystitis | Nitrofurantoin | 100 mg BID x 5 days | TMP-SMX DS BID x 3 days (if resistance <20%); fosfomycin 3 g x 1 |
| Uncomplicated pyelonephritis | Ciprofloxacin | 500 mg BID x 7 days | Levofloxacin 750 mg daily x 5 days; ceftriaxone 1 g IV + oral step-down |
| Complicated UTI/urosepsis | Piperacillin-tazobactam, cefepime, or meropenem | 10-14 days; de-escalate per culture | Guided by local antibiogram |
Uncomplicated pyelonephritis is treated with ciprofloxacin 500 mg twice daily for seven days or levofloxacin 750 mg once daily for five days. For moderate to severe presentations, ceftriaxone 1 g intravenously followed by oral step-down therapy is appropriate. Outpatient management is suitable if the patient can tolerate oral intake and is hemodynamically stable.
Complicated UTIs and urosepsis require empiric broad-spectrum antibiotic therapy tailored to local antibiograms, with options including piperacillin-tazobactam, cefepime, or meropenem. Source control is critical; for example, obstructing ureteral stones necessitate urgent decompression via ureteral stent placement or percutaneous nephrostomy. Antibiotic therapy should be de-escalated based on culture and sensitivity results within 48 to 72 hours. Treatment duration typically ranges from 10 to 14 days depending on clinical response.
Prevention of recurrent UTIs involves behavioral modifications such as post-coital voiding, maintaining adequate hydration, and avoiding spermicides. Vaginal estrogen therapy is beneficial in postmenopausal women by restoring Lactobacillus colonization. Continuous or post-coital prophylaxis with nitrofurantoin 50-100 mg nightly or post-coitally is effective. Methenamine hippurate offers a non-antibiotic alternative, and D-mannose shows limited but promising evidence.
<image>Flowchart algorithm for the management of recurrent UTI in women, showing initial evaluation with urinalysis and culture, risk factor modification, first-line and second-line prophylactic strategies, and indications for urologic workup</image>
Special Populations
In men, UTIs are always classified as complicated due to the potential involvement of the prostate. Treatment duration is longer, typically seven to fourteen days, with agents that achieve good prostatic penetration such as fluoroquinolones or trimethoprim-sulfamethoxazole. Urologic evaluation is recommended after the first UTI in young men or in cases of recurrent infections.
Catheter-associated UTIs (CAUTIs) are diagnosed by the presence of symptoms along with a urine culture showing at least 10^3 CFU/mL from a catheterized specimen. Asymptomatic bacteriuria in catheterized patients should not be treated. Exchanging the catheter at the time of antibiotic initiation improves outcomes. Prevention strategies include early catheter removal, use of closed drainage systems, and aseptic insertion techniques.
In pregnancy, asymptomatic bacteriuria must be screened for and treated due to the risk of pyelonephritis and preterm labor. Safe antibiotic options include nitrofurantoin (avoided near term), cephalosporins, and amoxicillin-clavulanate. Fluoroquinolones and tetracyclines are contraindicated.
Key Clinical Pearls
It is essential to obtain a urine culture before initiating antibiotics in complicated UTIs to guide targeted therapy. Asymptomatic bacteriuria should only be treated in pregnancy, prior to urologic procedures, and in renal transplant recipients. An obstructed infected kidney constitutes a urologic emergency requiring immediate decompression. Antibiotic stewardship and familiarity with local antibiograms are critical to combat the rising problem of antimicrobial resistance. The presence of pyuria without bacteriuria should prompt consideration of alternative diagnoses such as urethritis, interstitial cystitis, or urogenital tuberculosis.
References
- Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(5):e103-e120.
- Bonkat G, Bartoletti R, Bruyère F, et al. EAU Guidelines on Urological Infections. European Association of Urology, 2023.
- Hooton TM. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028-1037.
- Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110.
